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Dear Sir,
The risk of postoperative complications such as fistula
recurrence or incontinence increases in patients with
recurrent fistulas and high transsphincteric and supra-
sphincteric fistulas [1, 2]. Due to the large number of
postoperative complications, in recent years, there have
been some attempts to treat this disease conservatively.
Methods of treatment include tissue adhesives and plugs
that close the internal orifice as well as autologous growth
factors that are present in the platelet-rich plasma and used
as ‘‘natural glue’’ to close the lumen of the fistula.
Autologous platelet-rich plasma (APRP) is platelet
concentration derived from centrifuged full blood collected
from a patient right before surgery. The platelet-rich
plasma (PRP) obtained using the Gravitational Platelet
Separation III System (GPS III, Biomet Merck, UK)
constitutes 10 % of the original volume of the collected
blood and more than 90 % of its mass is made of platelets.
Platelet-rich plasma preparation is administered to the fis-
tula tract following curettage (Fig. 1). We report our
experience with the GPS System in 2 patients with anal
fistula.
A 50-year-old male underwent surgery for recurrent
suprasphincteric posterior horseshoe fistula at our unit. At a
time of surgery curettage of the fistula tract was performed,
and then a GPS III preparation was administered to the
fistula tract. The patient was discharged home 2 days after
surgery. Fourteen days after surgery, the patient presented
at the ward due to an inflammatory infiltration. Two
months after surgery, a follow-up examination revealed
fistula recurrence.
A 37-year-old male with recurrent intersphincteric
anterior fistula-in-ano, and with a narrow, transsphincteric
branch running towards the puborectalis loop also under-
went surgical treatment at our unit. At a time of surgery,
the main tract of the fistula was removed and APRP (GPS
III) was administered to the narrow lateral tract following
curettage. The patient was discharged home on postoper-
ative day 3. No recurrence of the fistula was reported
within the 6-month follow-up period.
The first experiences with using growth factors were
related to the treatment of patients with chronic skin ulcers
[3]. At present, indications for using APRP therapy are
being expanded. APRP is used in burn units and for the
treatment of non-healing wounds. There are also reports of
using APRP for the treatment of tendon injuries, muscle
injuries, degenerative lesions of tendons and joints and
bone voids, mainly in maxillofacial surgery. APRP therapy
is also offered by aesthetic surgery centres, where it is used
to fill deep wrinkles.
In the healing process, thrombin stimulates plate-
let alpha-granules to release growth factors which, through
appropriate stem cell receptors, stimulate stem cell
differentiation.
Reports of using autologous growth factors for the
treatment of fistula-in-ano date back to the late 1990s. In
1999, a paper on the treatment of patients with recurrent
fistula-in-ano was published [2]. It described a group of 30
patients with complex fistulas, rectovaginal fistulas and
vesicorectal fistulas. The cure rate was 60 %. A similar
cure rate was reported by Cintron et al. [1].
In the literature, there are reports of using APRP as an
element of multi-stage treatment of fistula-in-ano. The first
stage involves inserting a loose seton through the fistula
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tract in order to drain and heal any local inflammatory
lesions. The second stage involves APRP administration,
which resulted in fistula healing in as many as 75 % of
patients [4]. Hagen et al. [5] used the two-stage method,
and in 2009 they published the results of administering
APRP to 10 patients with high transsphincteric fistulas. The
first stage of treatment involved draining the fistula tract
and then closing the internal opening with a patch of
mucous membrane and filling the tract with APRP. After
almost 2 years of follow-up, fistula recurrence was
observed in 10 % of the patients.
Available publications include papers that present small
groups of patients, different types of fistulas qualified for
APRP treatment and different methods of surgery. How-
ever, the results are encouraging since this method has no
negative effect on anal sphincter function.
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